Immunodominant CD4 + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
- 14 June 2004
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 101 (25) , 9363-9368
- https://doi.org/10.1073/pnas.0403271101
Abstract
There is increasing evidence showing the involvement of CD4 + T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with ISCOMATRIX adjuvant and injected into patients intramuscularly. Autologous dendritic cells pulsed with NY-ESO-1 ISCOMATRIX in combination with overlapping synthetic peptides were used to identify immunodominant T cells from a vaccinated patient. We show here the identification and characterization of two novel CD4 + T cell epitopes. T cells specific to these epitopes not only recognized autologous dendritic cells loaded with NY-ESO-1 but also NY-ESO-1-expressing tumor cell lines treated with IFN-γ. One of the two responses identified was greater than the previously identified immunodominant HLA-DP4-restricted response and correlated with NY-ESO-1-specific CD8 + T cell induction after vaccination. This T cell response was vaccinated in most patients who expressed HLA-DR2. This study has systematically surveyed patients vaccinated with full-length tumor antigen for a vaccinated CD4 helper T cell response.Keywords
This publication has 21 references indexed in Scilit:
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humansProceedings of the National Academy of Sciences, 2004
- Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responsesProceedings of the National Academy of Sciences, 2003
- CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytesNature, 2003
- Novel Role of CD8+T Cells and Major Histocompatibility Complex Class I Genes in the Generation of Protective CD4+Th1 Responses during Retrovirus Infection in MiceJournal of Virology, 2002
- CD4+T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody productionProceedings of the National Academy of Sciences, 2001
- HLA-DR-Promiscuous T Cell Epitopes fromPlasmodium falciparumPre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II AllelesThe Journal of Immunology, 2000
- Augmentation of Human Influenza A Virus-Specific Cytotoxic T Lymphocyte Memory by Influenza Vaccine and Adjuvanted Carriers (ISCOMS)Virology, 1999
- Extracellular processing of peptide antigens that bind class I major histocompatibility molecules.The Journal of Experimental Medicine, 1992
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypesHuman Immunology, 1987